Mircera: manufacturer advises switch to alternative owing to stock shortage

Roche has announced a shortage of methoxypolyethylene glycol-epoetin beta (Mircera) owing to manufacturing issues.

Methoxypolyethylene glycol-epoetin beta is a long-acting analogue of erythropoietin, the hormone that stimulates the production of red blood cells | SCIENCE PHOTO LIBRARY
Methoxypolyethylene glycol-epoetin beta is a long-acting analogue of erythropoietin, the hormone that stimulates the production of red blood cells | SCIENCE PHOTO LIBRARY

Roche has sent a letter to all healthcare professionals advising that it is expecting to run out of stock entirely and is therefore recommending that patients be switched to an alternative erythropoiesis-stimulating agent.

Advice to clinicians

Mircera is licensed for the treatment of symptomatic anaemia associated with chronic kidney disease in adults. Healthcare professionals are advised not to initiate treatment with Mircera in new patients and to clinically assess patients currently receiving Mircera to identify a suitable alternative product. Close monitoring of haemoglobin levels and for immunological reactions is recommended when switching.

Alternative preparations

Other erythropoietin products that are licensed for the same indication as Mircera include darbepoetin alfa (Aranesp), epoetin alfa (Binocrit, Eprex), epoetin beta (NeoRecormon), epoetin theta (Eporatio) and epoetin zeta (Retacrit).

View Mircera drug records

Further information: Roche Products Ltd


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases